Weekly paclitaxel in ovarian cancer-the latest success story.
作者信息
Jain A, Dubashi B, Reddy K S, Jain P
机构信息
Medical Oncology, Regional Cancer Center, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India,
出版信息
Curr Oncol. 2011 Jan;18(1):16-7. doi: 10.3747/co.v18i1.680.
Abstract
摘要
相似文献
1
Weekly paclitaxel in ovarian cancer-the latest success story.
Curr Oncol. 2011 Jan;18(1):16-7. doi: 10.3747/co.v18i1.680.
2
Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?每周紫杉醇联合卡铂与每 3 周紫杉醇联合卡铂治疗晚期卵巢癌：哪种是最佳辅助化疗方案？
J Gynecol Oncol. 2018 Nov;29(6):e96. doi: 10.3802/jgo.2018.29.e96.
3
Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer.腹腔内注射紫杉醇和顺铂与剂量密集型紫杉醇和卡铂用于Ⅲ期卵巢癌患者的比较。
J Oncol Pharm Pract. 2020 Oct;26(7):1566-1574. doi: 10.1177/1078155219899460. Epub 2020 Jan 16.
4
Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer.每周使用紫杉醇和每3周使用卡铂进行剂量密集化疗用于复发性卵巢癌。
Taiwan J Obstet Gynecol. 2020 Jan;59(1):21-27. doi: 10.1016/j.tjog.2019.10.003.
5
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
6
Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer.每周卡铂和紫杉醇：与卵巢癌一线治疗中三周方案的回顾性比较。
Oncologist. 2021 Jan;26(1):30-39. doi: 10.1634/theoncologist.2020-0196. Epub 2020 Aug 12.
7
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.晚期卵巢癌新辅助化疗后贝伐珠单抗辅助剂量密集化疗和维持治疗的 II 期 AGOG/TGOG 试验。
Eur J Obstet Gynecol Reprod Biol. 2021 Jul;262:13-20. doi: 10.1016/j.ejogrb.2021.04.017. Epub 2021 Apr 18.
8
Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?最佳减瘤术治疗 III 期卵巢癌：腹腔内化疗还是静脉化疗？
Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S20-3. doi: 10.1111/IGC.0b013e3181f60d26.
9
[Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].[每周一次紫杉醇给药治疗铂耐药上皮性卵巢癌疗效的临床研究]
Gan To Kagaku Ryoho. 2004 Dec;31(13):2141-4.
10
Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer.卵巢癌腹腔内卡铂和剂量密集静脉注射紫杉醇的治疗耐受性及副作用
J Obstet Gynaecol Can. 2018 Oct;40(10):1283-1287.e1. doi: 10.1016/j.jogc.2018.01.028.
引用本文的文献
1
The Persistent Power of the Taxane/Platin Chemotherapy.紫杉烷/铂类化疗的持久效力
Cancers (Basel). 2025 Apr 2;17(7):1208. doi: 10.3390/cancers17071208.
2
Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.紫杉醇与CDK4/6抑制剂联合用于卵巢癌治疗的理论依据——紫杉醇的非有丝分裂机制
Front Oncol. 2022 Sep 15;12:907520. doi: 10.3389/fonc.2022.907520. eCollection 2022.
3
Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.低强度超声作为紫杉烷/紫杉醇诱导的细胞毒性的解毒剂
J Cancer. 2022 Apr 18;13(7):2362-2373. doi: 10.7150/jca.71263. eCollection 2022.
4
Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.打破恶性细胞核作为紫杉醇的一种非有丝分裂机制。
J Cancer Biol. 2021;2(4):86-93. doi: 10.46439/cancerbiology.2.031.
5
Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.低强度超声暴露可消除乳腺癌和卵巢癌细胞中的紫杉醇细胞毒性。
BMC Cancer. 2021 Sep 1;21(1):981. doi: 10.1186/s12885-021-08722-7.
6
Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.蜂蛇毒液毒素的抗癌活性——对卵巢癌的综述
Molecules. 2018 Mar 19;23(3):692. doi: 10.3390/molecules23030692.
7
A novel melittin-MhIL-2 fusion protein inhibits the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth.一种新型蜂毒素-MhIL-2 融合蛋白可抑制人卵巢癌细胞 SKOV3 体外和体内肿瘤生长。
Cancer Immunol Immunother. 2013 May;62(5):889-95. doi: 10.1007/s00262-013-1401-2. Epub 2013 Feb 27.
8
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.环氧化酶-1选择性抑制剂与紫杉醇联合应用对卵巢癌体内增殖、凋亡及血管生成的影响
Oncol Lett. 2012 Jul;4(1):168-174. doi: 10.3892/ol.2012.688. Epub 2012 Apr 23.
本文引用的文献
1
Chemotherapy: Current drugs still have potential in advanced ovarian cancer.化疗：现有药物在晚期卵巢癌中仍有潜力。
Nat Rev Clin Oncol. 2010 Apr;7(4):191-3. doi: 10.1038/nrclinonc.2010.37.
2
Dose-dense chemotherapy in advanced ovarian cancer.
Lancet. 2009 Oct 17;374(9698):1303-5. doi: 10.1016/S0140-6736(09)61305-2. Epub 2009 Sep 18.
3
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.每周一次密集剂量紫杉醇联合每3周一次卡铂治疗晚期卵巢癌：一项3期、开放标签、随机对照试验。
Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.
4
Weekly paclitaxel in the adjuvant treatment of breast cancer.每周一次紫杉醇用于乳腺癌辅助治疗
N Engl J Med. 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056.
5
Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.卵巢癌的腹腔内化疗：综述与展望
J Clin Oncol. 2007 Jul 10;25(20):2867-72. doi: 10.1200/JCO.2007.10.8167.
6
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.顺铂和紫杉醇腹腔内给药治疗卵巢癌
N Engl J Med. 2006 Jan 5;354(1):34-43. doi: 10.1056/NEJMoa052985.
7
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.每周一次紫杉醇（80mg/m²）用于铂类和紫杉醇耐药的卵巢癌及原发性腹膜癌的II期试验：一项妇科肿瘤学组研究
Gynecol Oncol. 2006 Jun;101(3):436-40. doi: 10.1016/j.ygyno.2005.10.036. Epub 2005 Dec 2.
8
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.一项针对潜在铂敏感型卵巢癌和腹膜癌患者的II期试验，该试验采用每周一次紫杉醇和每三周一次卡铂的给药方案。
Gynecol Oncol. 2005 Feb;96(2):296-300. doi: 10.1016/j.ygyno.2004.03.046.
Zotero 插件